D-Plus Hemolytic Uremic Syndrome
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About D-Plus Hemolytic Uremic Syndrome

What is the definition of D-Plus Hemolytic Uremic Syndrome?
D-plus (diarrhea positive) hemolytic uremic syndrome, also known as STEC hemolytic uremic syndrome, is a rare disease that affects children between one and ten years old which is characterized by low levels of red blood cells (hemolytic anemia), low platelets (thrombocytopenia), and an inability of the kidneys to process waste products from the blood (uremia). D-plus hemolytic uremic syndrome develops after certain bacterial infections, such as Escherichia. coli (E. coli) that cause diarrhea.
What are the symptoms of D-Plus Hemolytic Uremic Syndrome?
Symptoms of D-plus hemolytic uremic syndrome can be mild or severe and usually appear after an illness that is characterized by fever, abdominal cramps and pain, nausea, vomiting, and bloody diarrhea (gastroenteritis). Symptoms of D-plus hemolytic uremic syndrome may include paleness, irritability, weakness, reduced urinary output or no urine, lethargy, acute kidney injury, chronic kidney disease, protein in the urine, unexplained bruising, nosebleeds, high blood pressure, gallstones, neurological deficits, confusion, partial paralysis, seizures, coma, pancreatitis, and diabetes mellitus.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for D-Plus Hemolytic Uremic Syndrome?
Treatment for D-minus hemolytic uremic syndrome may include intravenous fluid and nutrition replacement, kidney or peritoneal dialysis, blood transfusion, vasodilators, medications, such as eculizumab and ultomiris (favulizumab-cwyz), plasma exchange (plasmapheresis), immunosuppressive therapy, or kidney transplantation.
Who are the top D-Plus Hemolytic Uremic Syndrome Local Doctors?
Robert A. Brodsky
Elite in D-Plus Hemolytic Uremic Syndrome
Pathology | Hematology | Oncology
Elite in D-Plus Hemolytic Uremic Syndrome
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Elite in D-Plus Hemolytic Uremic Syndrome
Elite in D-Plus Hemolytic Uremic Syndrome
Via Della Commenda 9, 
Milan, IT 

Gianluigi Ardissino practices in Milan, Italy. Mr. Ardissino is rated as an Elite expert by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Hemolytic-Uremic Syndrome, D-Minus Hemolytic Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in D-Plus Hemolytic Uremic Syndrome
Elite in D-Plus Hemolytic Uremic Syndrome

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
Languages Spoken:
English
Offers Telehealth

Spero Cataland is a Hematologist in Columbus, Ohio. Dr. Cataland is rated as an Elite provider by MediFind in the treatment of D-Plus Hemolytic Uremic Syndrome. His top areas of expertise are Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy.

What are the latest D-Plus Hemolytic Uremic Syndrome Clinical Trials?
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome

Summary: The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).

What are the Latest Advances for D-Plus Hemolytic Uremic Syndrome?